Gardner Lewis Asset Management L P Makes New $668,000 Investment in Danaher Co. (NYSE:DHR)

Gardner Lewis Asset Management L P acquired a new stake in shares of Danaher Co. (NYSE:DHR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,673 shares of the conglomerate’s stock, valued at approximately $668,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Gilbert & Cook Inc. increased its stake in shares of Danaher by 4.9% during the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock valued at $423,000 after buying an additional 86 shares during the period. Accretive Wealth Partners LLC boosted its holdings in Danaher by 12.9% in the fourth quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock valued at $840,000 after acquiring an additional 414 shares in the last quarter. Gryphon Financial Partners LLC increased its position in Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after purchasing an additional 468 shares during the period. TrinityPoint Wealth LLC raised its holdings in Danaher by 12.4% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,469 shares of the conglomerate’s stock worth $340,000 after purchasing an additional 162 shares in the last quarter. Finally, Hillsdale Investment Management Inc. lifted its position in shares of Danaher by 38.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 215 shares of the conglomerate’s stock worth $50,000 after purchasing an additional 60 shares during the period. 79.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Evercore ISI reduced their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Robert W. Baird upped their price target on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, TD Cowen raised their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Trading Down 1.3 %

NYSE:DHR opened at $272.48 on Wednesday. The stock has a market cap of $201.82 billion, a price-to-earnings ratio of 46.18, a PEG ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average price is $265.91 and its 200-day moving average price is $256.78. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.05 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. On average, equities research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.